GleamWall
中文EN

BGLC BioNexus Gene Lab Corp

Services-Medical Laboratories · Nasdaq · SEC CIK 1737523 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-93.3%
TTM net income YoY-27.2%
TTM EPS YoY-130.3%
Revenue 3-yr CAGR-60.6%
Net income 3-yr CAGR—

Margins

Gross margin2.0%
Operating margin-461.1%
Net margin-463.1%
FCF margin20.5%
EBITDA margin-443.3%

Returns

ROE-40.7%
ROA-35.7%
ROIC (approx.)-37.8%
Asset turnover0.08x

Leverage & solvency

Liabilities / assets14.1%
Debt / equity0.01x
Current ratio3.74x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-0.05x
Accruals ratio-37.3%
Payout ratio—
Capex / revenue0.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$47,917$76,156$22,842$483,760$2.54M$2.26M$2.14M$2.52M
Cost of revenue$43,429$63,174$23,632$487,743$2.17M$1.89M$1.79M$2.21M
Gross profit$4,488$12,982-$790-$3,983$377,685$368,022$343,493$309,234
R&D expense$13,578$13,671$14,487$11,098$14,876$12,557$12,139$17,396
SG&A expense$311,387$298,526$327,669$181,095$448,791$516,790$391,876$165,932
Operating income-$1.05M-$282,396-$540,490-$1.03M-$705,609-$611,293-$618,418-$416,220
Pretax income-$1.05M-$286,451-$543,575-$1.04M-$708,991-$616,172-$623,327-$422,032
Income tax$0$0$0$0$0$0$0-$80,701
Net income-$1.05M-$286,451-$543,575-$1.04M-$708,991-$616,172-$623,327-$348,319
EBITDA-$1.02M-$254,331-$512,197-$1.00M-$676,608-$583,493-$591,776-$386,671
EPS (diluted)-0.39-0.12-0.23—-0.40-0.34-0.35—
Weighted avg. shares (diluted)2.69M2.42M2.42M—1.80M1.80M1.80M—
Balance sheet
Cash & equivalents$865,804$1.23M$1.34M$2.38M$1.36M$1.54M$2.09M$2.89M
Receivables$38,142$15,544$79,860$505,885$1.52M$1.85M—$1.38M
Inventory$636,226$652,892$667,154$676,703$1.01M$1.22M$1.18M$1.39M
Current assets$4.19M$4.94M$5.20M$5.37M$5.63M$6.38M$6.54M$7.43M
PP&E, net$1.51M$1.54M$1.58M$1.60M$1.57M$1.59M$1.52M$1.52M
Total assets$8.76M$8.73M$9.04M$9.25M$7.62M$9.42M$9.48M$10.43M
Current liabilities$1.12M$812,938$796,470$520,957$678,023$1.76M$1.56M$1.95M
Long-term debt$54,375———————
Total debt$54,375———————
Total liabilities$1.24M$947,981$946,877$637,856$804,966$1.90M$1.71M$2.11M
Shareholders' equity$7.52M$7.78M$8.09M$8.61M$6.82M$7.52M$7.77M$8.32M
Net debt-$811,429———————
Shares outstanding2.93M2.42M2.42M2.42M1.80M1.80M17.97M1.80M
Cash flow statement
Operating cash flow-$257,465-$422,491-$147,671$961,062-$1.24M-$737,907-$824,072$219,203
Capital expenditure$2,528$250$325$977$5,483$21,459$9,052$4,022
Free cash flow-$259,993-$422,741-$147,996$960,085-$1.24M-$759,366-$833,124$215,181
Investing cash flow-$12,679$416,140-$13,988-$5,717$994,646-$28,532-$15,646$494,158
Financing cash flow$103,999$13,607$59,709$266,544$34,187-$1,030-$860-$142,387
Depreciation & amortization$27,682$28,065$28,293$28,430$29,001$27,800$26,642$29,549
Stock-based compensation$799,998——$794,770$0——$0

Free plan shows the latest 8 periods; Pro shows all 35 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.